Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 269)
Posted On: 10/04/2018 6:27:23 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans to Grow its Global Patent Application Portfolio to 150-200 within Two Years
- LXRP files for tenth patent family, expanding the applicability of its DehydraTECH platform relating to tobacco leaves delivering compounds that may or may not include nicotine
- LXRP receives three new Australian patents and two new notices of allowance from the U.S.; if all are issued, LXRP would then hold 12 issued patents within its first patent family
- The company out-licenses its technology that promotes healthier and faster ingestion methods in any country where it already has a patent or is patent-pending
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH ingestion technology platform, is building its strategic intellectual property (IP) portfolio and plans to grow its patent applications to 150-200 worldwide within two years (http://nnw.fm/na2R0).
It has filed a provisional application in a tenth patent family relating to the applicability of DehydraTECH’s imparting benefits to tobacco leaves to deliver compounds that may or may not include nicotine. That patent family is “Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof.”
Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology that has shown quicker and more effective delivery of cannabinoids and nicotine. Its IP portfolio already includes a patent for oral delivery of all cannabinoids.
DehydraTECH is its proprietary absorption technology platform. LXRP has now filed a total of more than 50 patent applications across nine current patent families. It is preparing applications for at least six more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families.
It has received three more patents in Australia and two notices of allowance by the U.S. Patent & Trademark Office (USPTO). LXRP expects to receive corresponding patents in the U.S. prior to year-end 2018 and also expects two more new patents in Australia to be received prior to year-end (http://nnw.fm/E1x1H).
If all are issued, LXRP would then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new Australian patents are projected to expire on June 10, 2035, it said.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- LXRP files for tenth patent family, expanding the applicability of its DehydraTECH platform relating to tobacco leaves delivering compounds that may or may not include nicotine
- LXRP receives three new Australian patents and two new notices of allowance from the U.S.; if all are issued, LXRP would then hold 12 issued patents within its first patent family
- The company out-licenses its technology that promotes healthier and faster ingestion methods in any country where it already has a patent or is patent-pending
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH ingestion technology platform, is building its strategic intellectual property (IP) portfolio and plans to grow its patent applications to 150-200 worldwide within two years (http://nnw.fm/na2R0).
It has filed a provisional application in a tenth patent family relating to the applicability of DehydraTECH’s imparting benefits to tobacco leaves to deliver compounds that may or may not include nicotine. That patent family is “Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof.”
Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology that has shown quicker and more effective delivery of cannabinoids and nicotine. Its IP portfolio already includes a patent for oral delivery of all cannabinoids.
DehydraTECH is its proprietary absorption technology platform. LXRP has now filed a total of more than 50 patent applications across nine current patent families. It is preparing applications for at least six more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families.
It has received three more patents in Australia and two notices of allowance by the U.S. Patent & Trademark Office (USPTO). LXRP expects to receive corresponding patents in the U.S. prior to year-end 2018 and also expects two more new patents in Australia to be received prior to year-end (http://nnw.fm/E1x1H).
If all are issued, LXRP would then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new Australian patents are projected to expire on June 10, 2035, it said.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)